2013-02-25 12:08:32 -

This information was released for public disclosure on February 25, 2013 at
12.00 am CET.

CellaVision today announced that the Company has signed a distribution agreement
with global healthcare company, Abbott, to market and distribute CellaVision's
leading-edge digital microscopy products to the hematology market in Europe and
the countries in former Soviet Union (CIS).  The non-exclusive agreement
comprises most European countries*, and is effective from February 25, 2013.

"I am very pleased to enter into this agreement with Abbott in Europe. By
cooperating with strategic partners who have a high market presence and an
extensive sales and support network, CellaVision anticipates further business
expansion. By adding yet another distributor to our sales channels, we have now
given more clinical laboratories in Europe access to our digital microscopy
products, regardless of their hematology   vendor", said Yvonne Mårtensson,
CellaVision CEO.

Europe is one of CellaVision's major growth markets. The transition from manual
microscopy to CellaVision's method has been in progress for a few years in the
European countries. In 2012 Europe accounted for 33 percent of the company's
total sales.

* In 2012 separate agreements were signed for Sweden, Norway and Denmark. These
agreements differ from the European distribution agreement in that CellaVision
is responsible for installation and support.

For further information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82 | Email: yvonne.martensson@cellavision.com

About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The products rationalize manual laboratory work,
and secure and support effective workflows and skills development within and
between hospitals. The company has leading-edge expertise in image analysis,
artificial intelligence and automated microscopy. In most countries sales are
via global partners. Products are sold directly in the Nordic countries and via
subsidiaries in the US, Canada and Japan. In 2012 sales were SEK 170 million and
sales continue to increase, with a growth target of at least 15 % per year over
an economic cycle. CellaVision's registered office is in Lund, Sweden. The share
is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at
www.cellavision.com.

Publication
This information is disclosed by CellaVision AB (publ) pursuant to the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public disclosure on February 25, 2013 at 12.00 am
CET.


Press release as PDF: 
 hugin.info/132164/R/1680716/549206.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1680716]